MSFP
NKTR icon

Mark Sheptoff Financial Planning’s Nektar Therapeutics NKTR Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-320
Closed -$510K – 382
2018
Q1 		$510K Sell
320
-87
-21% -$112K 0.35% 63
2017
Q4 		$364K Hold
407
– – 0.24% 82
2017
Q3 		$146K Buy
407
+180
+79% +$56.3K 0.1% 125
2017
Q2 		$66K Buy
227
+174
+328% +$50.3K 0.05% 159
2017
Q1 		$19K Sell
53
-154
-74% -$34.6K 0.01% 231
2016
Q4 		$38K Buy
207
+67
+48% +$13.6K 0.03% 190
2016
Q3 		$36K Buy
+140
New +$36K 0.03% 188

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Mark Sheptoff Financial Planning's NKTR Position: Q2 2018 in Review

Mark Sheptoff Financial Planning sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 320 shares — an estimated $510K sold.

Mark Sheptoff Financial Planning first reported a position in NKTR in Q3 2016 and held it in 7 quarters. The position peaked at $510K in Q1 2018. 379 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

  • Mark Sheptoff Financial Planning reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Mark Sheptoff Financial Planning sold 320 Nektar Therapeutics shares in Q2 2018, an estimated $510K.
  • Mark Sheptoff Financial Planning first reported a position in Nektar Therapeutics in Q3 2016 and held it in 7 quarters.
  • Mark Sheptoff Financial Planning's Nektar Therapeutics position peaked at $510K in Q1 2018.
  • 379 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Mark Sheptoff Financial Planning's 13F filing for Q2 2018, filed 9 Aug 2018.